CareDx (NASDAQ:CDNA) CFO Sells $166,271.13 in Stock

CareDx, Inc. (NASDAQ:CDNA – Get Free Report) CFO Keith Kennedy sold 2,097 shares of the firm’s stock in a transaction dated Thursday, November 12th. The stock was sold at an average price of $79.29, for a total value of $166,271.13. Following the transaction, the chief financial officer directly owned 199,147 shares in the company, valued at approximately $15,790,365.63. The trade was a 1.04% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Keith Kennedy also recently made the following trade(s):

  • On Thursday, November 5th, Keith Kennedy sold 61,961 shares of CareDx stock. The stock was sold at an average price of $77.82, for a total value of $4,821,805.02.

CareDx Trading Down 5.3%

Shares of CareDx stock traded down $4.16 on Monday, hitting $73.72. The stock had a trading volume of 1,030,751 shares, compared to its average volume of 981,669. CareDx, Inc. has a 52-week low of $15.15 and a 52-week high of $90.87. The stock has a market cap of $3.87 billion, a price-to-earnings ratio of 30.85 and a beta of 2.50. The company’s 50 day moving average price is $66.34 and its 200 day moving average price is $36.70.

CareDx (NASDAQ:CDNA – Get Free Report) last announced its earnings results on Thursday, October 29th. The company reported $0.70 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.25 by $0.45. The firm had revenue of $139.36 million during the quarter, compared to analysts’ expectations of $121.96 million. CareDx had a return on equity of 9.74% and a net margin of 25.86%. The business’s revenue was up 39.3% on a year-over-year basis. During the same period in the prior year, the firm earned $0.03 EPS. Analysts predict that CareDx, Inc. will post 1.00 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on the company. BTIG Research increased their price objective on CareDx from $81.00 to $92.00 and gave the company a “buy” rating in a report on Friday, October 30th. Weiss Ratings raised shares of CareDx from a “hold (c)” rating to a “hold (c+)” rating in a report on Thursday, October 8th. Zacks Research upgraded shares of CareDx from a “hold” rating to a “strong-buy” rating in a research report on Thursday, November 5th. HC Wainwright reiterated a “neutral” rating and issued a $46.00 price target on shares of CareDx in a research report on Friday, July 31st. Finally, Craig Hallum upgraded shares of CareDx from a “hold” rating to a “buy” rating and set a $64.00 price target for the company in a research note on Monday, August 3rd. One research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and four have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $70.33.

Check Out Our Latest Research Report on CDNA

Hedge Funds Weigh In On CareDx

Several institutional investors have recently added to or reduced their stakes in the stock. Squarepoint Ops LLC raised its stake in CareDx by 759.5% during the 2nd quarter. Squarepoint Ops LLC now owns 141,623 shares of the company’s stock valued at $4,036,000 after acquiring an additional 125,146 shares during the last quarter. Canada Pension Plan Investment Board acquired a new stake in CareDx during the 2nd quarter worth approximately $1,505,000. Corient Private Wealth LP acquired a new stake in CareDx during the 2nd quarter worth approximately $654,000. Bank of New York Mellon Corp purchased a new position in shares of CareDx in the 2nd quarter valued at approximately $4,874,000. Finally, Man Group plc purchased a new position in shares of CareDx in the 2nd quarter valued at approximately $3,618,000.

About CareDx

(Get Free Report)

CareDx, Inc. is a precision medicine company focused on organ transplantation. It develops and provides diagnostic tests and related services to help clinicians assess transplant recipients and monitor their health over time. Its offerings include AlloSure, a donor-derived cell-free DNA test used to help monitor for organ rejection, and AlloMap, a gene-expression test used in heart transplant care. CareDx also provides histocompatibility testing, clinical tools, and services designed to support patients and transplant care teams.

Read More

Insider Buying and Selling by Quarter for CareDx (NASDAQ:CDNA)

Receive News & Ratings for CareDx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CareDx and related companies with MarketBeat.com's FREE daily email newsletter.